Immunogenicity and safety of Sanofi Pasteur's Avaxim 80U pediatric vaccine followed by booster dose
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors Sanofi; sanofi pasteur
- 22 Sep 2008 Primary outcome identified as providing information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine as reported by ClinicalTrials.gov.
- 22 Sep 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 22 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.